Skip to content

Electroacupuncture for mammary hyperplasia: a randomized controlled trial

Electroacupuncture for mammary hyperplasia: a randomized controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006676
Enrollment
Unknown
Registered
2022-10-02
Start date
2022-10-10
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperplasia of mammary glands

Interventions

control group:sham electropuncture

Sponsors

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1)Meet the diagnostic criteria of mammary hyperplasia; 2)VAS score > 3 for most painful breast pain in 7 days before menstruation in previous menstrual cycle;3)Women aged between 18 and 55 with regular menstrual cycle ( 28±7 days), and menstrual period (3-7 days);4)have not used Chinese / Western medicine or acupuncture treatment for breast hyperplasia in the past 3 months; 5)signed informed consent and are willing to cooperate with the treatment. Note: patients who meet the above 5 criteria were eligible.

Exclusion criteria

Exclusion criteria: 1)Pre-menstrual VAS score diary card records were less than 7 days during the screening period;2)Patients with breast cancer or prebreast lesions confirmed by mammography or B-ultrasound or breast hyperplasia accompanied by breast neoplasms, mastitis and other breast diseases with indications for surgery;3)Complicated with cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases, or digestive ulcer disease, or serious diseases affecting their survival (such as tumor or AIDS), or mental patients;4)pregnancy, lactation, menopause, or have a pregnancy plan in 6 months;5)patients who have taken sex hormone drugs or contraceptives in the last 3 months;6)those who are participating in or have recently participated in other clinical trials in the last 3 months. Note: All patients who met any of the above exclusion criteria were excluded.

Design outcomes

Primary

MeasureTime frame
VAS score of breast pain;

Secondary

MeasureTime frame
Serum sex hormone levels;Assessment of emotional state (SAS and SDS Self-rating Scales);Number of days with significant breast pain;Quality of Life Scale (SF-12 Scale);Breast mass size changes;

Countries

China

Contacts

Public ContactQIAO Hai-fa
1511006@sntcm.edu.cn1818220046518

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026